| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling pathway; NF-kB nuclear translocation; IL-8 production; ICAM-1 expression; Inflammatory cytokine pathways
|
|---|---|
| ln Vitro |
In hTNF-stimulated HLMVECs, pretreatment with Aeruginosin 865 (0.1-100 μg/mL) significantly inhibits IL-8 (EC50=3.5 μg/mL) and ICAM-1 (EC50=50.0 μg/mL) in a concentration-dependent manner. Even at far higher concentrations, aeruginosin 865 had no effect on the viability of HeLa or HepG2 cells[1]. Aeruginosin 865 (100-200 μM) exhibits little cytotoxic impact in NIH/ 3T3 cells but exhibits high-dose cytotoxicity in mouse fibrosarcoma cells[2].
Aeruginosin 865 (0.1–100 μg/mL) pretreatment significantly inhibits IL-8 production (EC50 = 3.5 μg/mL) and ICAM-1 expression (EC50 = 50.0 μg/mL) in hTNF-α-stimulated human lung microvascular endothelial cells (HLMVECs) in a concentration-dependent manner. Even at much higher concentrations, aeruginosin 865 has no effect on the viability of HeLa or HepG2 cells. In NIH/3T3 cells, it shows minimal cytotoxic effects at 100–200 μM, but exhibits high-dose cytotoxicity in mouse fibrosarcoma cells. |
| ln Vivo |
In vivo data for aeruginosin 865 are limited in publicly available literature. The compound is characterized primarily for its in vitro anti-inflammatory activity via NF-kB inhibition. Its in vivo pharmacokinetic profile, efficacy in animal models of inflammation, and toxicity profile have not been extensively reported. Further studies are required to establish its therapeutic potential and safety profile in vivo.
|
| Enzyme Assay |
For NF-kB translocation assays: culture HLMVECs, pretreat with aeruginosin 865 (0.1–100 μg/mL) for a defined period, then stimulate with hTNF-α. Fix cells, permeabilize, and stain with anti-NF-kB p65 antibody followed by fluorescent secondary antibody. Assess nuclear translocation by confocal laser scanning microscopy. For cytokine inhibition: measure IL-8 and ICAM-1 levels in culture supernatants or cell lysates by ELISA.
|
| Cell Assay |
For anti-inflammatory activity: culture HLMVECs in appropriate medium and pretreat with aeruginosin 865 at 0.1–100 μg/mL for 1–24 hours. Stimulate with hTNF-α (10 ng/mL) for 4–24 hours. Collect supernatants and measure IL-8 by ELISA. For ICAM-1 expression: harvest cells, stain with fluorescently labeled anti-ICAM-1 antibody, and analyze by flow cytometry or Western blot. For cytotoxicity: treat HeLa, HepG2, or NIH/3T3 cells with compound at 0.1–200 μM for 24–72 hours and assess viability by MTT assay.
|
| Animal Protocol |
In vivo protocols for aeruginosin 865 have not been extensively documented in published literature. Based on its in vitro anti-inflammatory mechanism, potential in vivo studies would involve administering the compound to rodent models of acute or chronic inflammation (e.g., carrageenan-induced paw edema, LPS-induced systemic inflammation) via intraperitoneal or intravenous routes. Doses would likely range from 1–50 mg/kg, with endpoints including inflammatory cytokine levels, edema volume, and histological assessment of tissue infiltration.
|
| References |
| Molecular Formula |
C41H64N6O14
|
|---|---|
| Molecular Weight |
864.9787
|
| Exact Mass |
864.448
|
| CAS # |
1611990-01-2
|
| PubChem CID |
154573759
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.2
|
| tPSA |
326
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
61
|
| Complexity |
1490
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CCCCCC(=O)O[C@H]1C[C@H]2C[C@@H](N([C@H]2C[C@@H]1O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O)C(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC4=CC=C(C=C4)O)O)C(=O)NCCCCN=C(N)N
|
| InChi Key |
GYBRMQYCKSSXID-RIDHWVDWSA-N
|
| InChi Code |
InChI=1S/C41H64N6O14/c1-4-5-6-9-31(50)59-29-19-23-18-27(36(54)44-14-7-8-15-45-41(42)43)47(26(23)20-30(29)60-40-34(53)32(51)33(52)35(61-40)39(57)58)38(56)25(16-21(2)3)46-37(55)28(49)17-22-10-12-24(48)13-11-22/h10-13,21,23,25-30,32-35,40,48-49,51-53H,4-9,14-20H2,1-3H3,(H,44,54)(H,46,55)(H,57,58)(H4,42,43,45)/t23-,25-,26+,27-,28-,29+,30+,32+,33+,34+,35+,40-/m1/s1
|
| Chemical Name |
(2S,3S,4S,5S,6R)-6-[[(2R,3aR,5S,6S,7aS)-2-[4-(diaminomethylideneamino)butylcarbamoyl]-5-hexanoyloxy-1-[(2R)-2-[[(2R)-2-hydroxy-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]-2,3,3a,4,5,6,7,7a-octahydroindol-6-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1561 mL | 5.7805 mL | 11.5610 mL | |
| 5 mM | 0.2312 mL | 1.1561 mL | 2.3122 mL | |
| 10 mM | 0.1156 mL | 0.5780 mL | 1.1561 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.